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Co-infection with HIV increases the morbidity and mortality associated with tuberculosis due to 
multiple factors including a poorly understood microbial synergy. We developed a novel small animal 
model of co-infection in the humanized mouse to investigate how HIV infection disrupts pulmonary 
containment of Mtb. Following dual infection, HIV-infected cells were localized to sites of Mtb-driven 
inflammation and mycobacterial replication in the lung. Consistent with disease in human subjects, 
we observed increased mycobacterial burden, loss of granuloma structure, and increased progression 
of TB disease, due to HIV co-infection. Importantly, we observed an HIV-dependent pro-inflammatory 
cytokine signature (IL-1β, IL-6, TNFα, and IL-8), neutrophil accumulation, and greater lung pathology 
in the Mtb-co-infected lung. These results suggest that in the early stages of acute co-infection in the 
humanized mouse, infection with HIV exacerbates the pro-inflammatory response to pulmonary Mtb, 
leading to poorly formed granulomas, more severe lung pathology, and increased mycobacterial burden 
and dissemination.
In the wake of the human immunodeficiency virus (HIV) pandemic, tuberculosis (TB) persists as a global health 
crisis that causes an estimated 1.5 million deaths per year1. TB is now the most significant health threat for those 
living with HIV/acquired immunodeficiency syndrome (AIDS) due to multifactorial effects of HIV infection to 
promote susceptibility to Mycobacterium tuberculosis (Mtb) infection or reactivation, exacerbate disease, increase 
drug resistance development, and compromise diagnosis2–6. Treatment of co-infected persons is further compli-
cated by drug interaction and malabsorption issues when combining anti-retroviral agents and TB chemotherapy 
[reviewed7]. Addressing these clinical challenges to reduce TB disease requires a much greater understanding of 
co-infection pathophysiology to inform development of novel interventions.
The human host tropism of HIV has limited the in vivo study of HIV and Mtb co-infection in an experimen-
tally controlled system. In human subjects, the loss of CD4+ T cells and functional suppression of T cells and anti-
gen presenting cell populations during chronic HIV is well known to impair the cell-mediated immune response 
to Mtb [reviewed in8,9]. The effect of infection and CD4+ T cell depletion by simian immunodeficiency virus 
(SIV) to compromise host containment of latent TB has been established through elegant studies in cynomolgus 
and rhesus macaque non-human primates (NHP) co-infection models10,11. A synergistic relationship between 
Mtb and HIV, however, occurs even before the loss of CD4+ T cells characteristic of AIDS6,12. Limited studies of 
human lung and bronchiole alveolar lavage fluid from co-infected subjects suggest that a poorly organized, and 
potentially inflammatory, pulmonary response can also occur13–15. To date, however, the immune disturbances 
and pathogenesis of TB/HIV in the lung prior to peripheral T cell depletion and generalized immune suppression 
are poorly understood due to the paucity of available tissue samples.
New animal models to complement clinical research with human subjects and basic studies of SIV and Mtb in 
NHP are needed. The bone marrow, liver, thymus (BLT) humanized mouse (HuMouse) has facilitated pioneering 
studies of HIV pathogenesis and treatment16–19. We previously developed a model of TB in the BLT HuMouse20 
that reproduces important hallmark features of human TB disease pathology, as described in recent independent 
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reviews21,22. In the current studies we applied our HuMouse model of experimental TB to investigate pulmonary 
Mtb/HIV-1 co-infection. We chose to model one of several important clinical scenarios, that of new pulmo-
nary Mtb infection in subjects with an existing HIV infection. Recent reports indicate that in HIV + subjects, 
Mtb infections are frequently a new event rather than reactivation of latent infections23–25. We observed that 
HIV-infected cells were localized to sites of Mtb-driven inflammation and mycobacterial replication in both 
human and HuMouse co-infected lung. We also observed increased mycobacterial burden and loss of granuloma 
structure due to HIV co-infection, consistent with disease in human subjects. Further, we show neutrophil infil-
tration and tissue necrosis due to HIV in the co-infected lung and increased production of pro-inflammatory 
cytokines and chemokines that recruit neutrophils. These results suggest that in the early stages of acute pulmo-
nary co-infection, HIV infection compromises antibacterial functions in the lung and activates non-protective 
inflammatory responses and neutrophil influx that can promote tissue damage.
Results
HIV replication in the Mtb-infected BLT humanized mouse. To emulate human HIV infection in BLT 
HuMice, animals were given 2,500 TCID50 of the JR-CSF strain of HIV-1 i.v. as described16. At 3 wk p.i. with HIV, 
some groups of animals were infected i.n. with 250 CFU of the H37Rv strain of Mtb as described20. Replication of 
HIV, based on detection of the p24 capsid protein by an ELISA assay employed in clinical settings to determine 
HIV status, was observed in the plasma and spleen at 8 wk post-HIV infection (Fig. 1A). Expression of p24, 
though variable, was detectable in HIV- and HIV/Mtb-infected mice from two independent studies. Co-infection 
with Mtb did not significantly alter viral load at this stage of infection (5 wk post-Mtb, and 8 wk post-HIV, infec-
tion). As previously observed in HuMice infected with the JR-CSF strain of HIV-1, CD4+ T-cell numbers decline 
slowly26. The moderate decrease in CD4+ T-cells observed in HIV-infected animal groups did not reach signifi-
cance compared to non-infected and Mtb-infected animals (Fig. 1B).
HIV p24 + cells localize to Mtb lesions in the lung. The role of HIV-infected cells in local immune 
suppression at the site of Mtb containment in protective granulomas is an important unknown in co-infection 
biology. We used hematoxylin and eosin (H&E) and immunohistochemistry (IHC) to assess tissue pathology 
associated with the presence and distribution of HIV + cells in Mtb-co-infected human and HuMouse lung tissue 
(Fig. 2). In the absence of HIV, the lesions observed in the lung of Mtb-infected animals were characteristic of 
TB where solid lesions arise from inflammation in the interstitium in response to Mtb-infected macrophages as 
shown with representative lung in Fig. 2A. In contrast, a much greater inflammatory cell influx with involvement 
of alveolar spaces was observed in the lung of Mtb/HIV co-infected animals (Fig. 2A). Histological examina-
tion of the lung tissue from HuMice infected with only HIV revealed no remarkable pathology compared to 
non-infected animals (Fig. 2A).
We found that HIV + cells trafficked to the lung in HuMice infected with HIV or co-infected with HIV and 
Mtb. In the absence of Mtb infection, HIV p24 + cells were occasionally found and were randomly distributed in 
Figure 1. HIV infection in HuMice co-infected with Mtb. BLT HuMice were infected i.v. with 2,500 TCID50 
of HIV-1 (JR-CSF) or mock infected (PBS). Subsets of HuMice from HIV or non-infected mice were infected 
i.n. with 250 CFU Mtb (H37Rv), 3 wk post-HIV infection. Data are means ± SEM from samples of non-infected 
control (n = 4) and three infection groups, HIV (n = 3), Mtb (n = 6) and Mtb/HIV (n = 8), of HuMice. (A) HIV 
p24 capsid protein was detected in HuMouse spleen and plasma by ELISA at 8 and 5 wk p.i. with HIV, and Mtb, 
respectively. Viral load did not differ among HIV and Mtb/HIV infection groups and results are thus pooled. 
(B) Flow cytometric detection of human CD45 + CD3 + CD4 + T cells in peripheral blood, shown as a percent of 
baseline (pre-HIV infection) value at 5 wk p.i. with Mtb.
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the lung parenchyma (Fig. 2B) as described27. In a subset of co-infected HuMice, HIV + cells were observed at sites 
of Mtb infection-driven inflammatory foci (Fig. S1A) at 3 wk p.i. with Mtb. Following 5 wk of co-infection, we 
observed that HIV + cells were localized almost exclusively to the sites of TB lesions including within developing 
pulmonary granulomas (Fig. 2B). The distribution of HIV + cells in co-infected HuMouse lung was similar to 
what we observed in co-infected human lung reference tissues. As shown with representative tissues from Mtb/
HIV co-infected human lung from autopsy cases (Fig. 2B), we found that HIV + cells are localized primarily to 
the lesion periphery in both newly forming solid lesions as well as in more progressed and necrotic TB granuloma.
Pulmonary growth of Mtb is increased by HIV co-infection prior to peripheral CD4+ T cell depletion. 
To determine the impact of HIV co-infection on the growth and dissemination of Mtb in HuMice, we measured 
colony-forming units (CFU) of mycobacteria in disrupted lung and liver tissue following necropsy. Analysis of 
randomly selected animals at 3 wk p.i. with Mtb revealed moderate mycobacterial growth in the lung that was 
similar among animals with mock or HIV co-infection (Fig. S1B). At 5 wk p.i., however, Mtb load was signifi-
cantly increased (> 1 log) in the lung of animals co-infected with HIV (Fig. 3A) in two independent groups of 
animals reconstituted with tissues from different human donors. Increased bacterial load due to HIV infection 
was also observed in the liver, though the change did not reach significance (p = 0.06) in one experimental group. 
These results were verified by visualization of AFB numbers using light microscopy (Fig. 3B). As shown in Fig. 3B 
relative to a similarly sized TB lesion, few AFB are observable in the lesions of an Mtb-infected HuMouse lung 
while greater AFB staining is observable in the co-infected lung. To determine if there was a positive relationship 
between relative lung viral load and bacterial burden among the co-infected animals, a Spearman’s Correlation 
analysis was performed. As shown in Fig. 3C, there was a positive, though weak, relationship between HIV p24 
levels and mycobacterial proliferation in lung tissue. A moderately positive relationship, however, was observed 
among HIV p24 and the % of granulomatous tissue in the co-infected animals (Figs 3C and 4B). These positive 
correlations were not statistically significant with this sample size.
HIV co-infection exacerbates pulmonary TB pathology. A limited number of observational studies of 
human lung has suggested that HIV disrupts TB granuloma architecture13,14, but controlled experiments still are 
needed given the paucity of animal models. To determine how HIV alters TB pathology in the HuMouse, we com-
pared lung tissue of Mtb and Mtb-HIV co-infected mice. Analysis of lung tissue from a subset of Mtb- or Mtb/
HIV-infected HuMice harvested at 3 wk p.i. with Mtb revealed mostly non-remarkable pathology with only occa-
sional foci of inflammation observed at sites of Mtb proliferation (Fig. S1). Surprisingly, a greater cellular influx 
was observed at these infrequent sites of Mtb-driven inflammation in HuMice with HIV co-infection (Fig. S1A). 
At this stage of disease in the HuMouse model the mycobacterial burden did not differ among HIV + and HIV- 
animals (Fig. S1B).
Figure 2. HIV-infected cells localize to Mtb lesions in the lung. Animals were infected i.v. with 2500 TCID50 
HIV-1 (JR-CSF) or mock infected and 3 wk later infected i.n. with 250 CFU of Mtb H37Rv. (A) Tissue pathology 
visualized by H&E staining shows normal lung architecture in a non-infected and HIV-infected animals and 
foci of inflammation in Mtb- and Mtb/HIV-infected lung. (B) Detection of HIV p24 by IHC (fast red) in lung of 
co-infected human reference samples at early and later stages of lesion progression, and in HIV- and HIV/Mtb-
infected HuMice 8 and 5 wk p.i. with HIV and Mtb, respectively.
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By 5 wk p.i., analysis of the gross lung demonstrated that co-infected mice had more numerous TB lesions 
compared to those infected with only Mtb (Fig. 4A). The lesion size varied among lesions within the lung, but 
overall the lesions in co-infected mice were larger (Fig. 4A). As a result, the percent of the lung occupied by granu-
lomatous tissue was significantly greater in co-infected animals (Fig. 4B). These larger lesions exhibited decreased 
organization of the granuloma structure due to the presence of diffuse cellular aggregations at the lesion site ver-
sus the smaller and more compact lesions observed in animals infected with Mtb alone (Fig. 4C). Importantly, the 
lesions from co-infected animals had a less discriminate distribution of AFB relative to lung pathology (Fig. 4C). 
In the lung of animals infected with Mtb, AFB were fewer and were localized primarily within solid lesions 
(Fig. 3B), suggesting successful containment by the host immune system. In contrast, AFB + cells were observed 
in co-infected lung within the granulomas, but also within macrophages in the alveolar spaces adjacent to poorly 
defined lesion peripheral zones (Figs 3B and 4C). Increased tissue necrosis accompanied by areas of nuclear kar-
yorrhectic debris, was also present in co-infected animals (Fig. 4D). Consistent with the reported role of necrotic 
tissue to promote mycobacterial growth28,29, large numbers of AFB were visualized within these necrotic tissue 
zones (Fig. 4D).
Co-infection with HIV promotes neutrophil accumulation in pulmonary TB granulomas. 
To determine the basis for exacerbated lung pathology due to co-infection, we investigated neutrophil influx in 
lung tissue of HuMice and of human reference tissues. Inflammatory lesions most similar in size and stage of 
organization were chosen through H&E visualization of pathology for assessment alongside tissue from HuMice 
(Fig. 5A). Neutrophils were stained using titration of an antibody specific to myeloperoxidase (MPO) (Fig. 5B). In 
the HuMouse, at 5 wk pi we observed solid and well organized lesions (Figs 4C and 5A) that were similar to smaller 
lesions found in human lung from a decedent with Mtb infection (Fig. 5A). Moderate numbers of neutrophils were 
distributed throughout the lung lesions from HuMice and human subjects infected with Mtb only, consistent with 
prior descriptions in human lung30 and other animal models of TB31–33. In contrast, in co-infected lung from both 
human subjects and HuMice, we observed sites of inflammatory pathology characterized by a poorly organized 
inflammatory influx (Fig. 5A). Detection of MPO revealed a marked increase in the numbers of neutrophils local-
ized to these poorly organized inflammatory areas in co-infected tissue (Fig. 5B). The specificity of staining in these 
necrotic tissues was confirmed using a non-specific primary antibody as a control (Fig. 5B, insert).
HIV co-infection activates excessive pro-inflammatory cytokine responses to Mtb in the 
lung. The pathologic findings of increased leukocyte trafficking and greater lesion pathology are suggestive 
of increased inflammation due to HIV in the setting of Mtb infection. To determine if a unique inflammatory 
response to pulmonary Mtb infection occurs in HuMice with HIV infection, we performed bioplex ELISA anal-
ysis of the lung supernatant from non-infected control animals, and animals infected with HIV, Mtb, and Mtb 
Figure 3. Pulmonary growth of Mtb is increased by HIV co-infection prior to peripheral CD4+ T cell 
depletion. (A) CFU enumeration of Mtb in lung and liver tissue of HuMice at 5 wk p.i. with Mtb from 
two independent studies. Statistically significant differences compared to non-infected are designated by 
*p < 0.05. (B) Increased bacterial growth confirmed by Ziehl-Neelson detection of AFB by light microscopy in 
representative lung of Mtb-infected (left) and Mtb/HIV co-infected mice (right). (C) Correlation between HIV 
p24 and mycobacterial proliferation or pathology in the lung of co-infected HuMice (n = 8) was determined 
using a Spearman’s rank correlation co-efficient (Rs).
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plus HIV. As shown in Fig. 6, the expression of most cytokines and chemokines in animals infected with only 
HIV were similar to the baseline presence observed in non-infected control animals (Fig. 6). The exceptions were 
a significant increase in MCP-1 and a trend towards increased IL-6 due to HIV infection. Consistent with the 
non-significant reduction of CD4+ T-cell populations that we observed at this stage of HIV infection (Fig. 1), 
there were no significant decreases in IFN-γ activation due to HIV co-infection with Mtb. As expected, sev-
eral cytokines and chemokines were significantly increased in the lung microenvironment due to Mtb infection, 
including pro-inflammatory cytokines (IL-1-β , IL-6, and TNF-α ) and chemokines (MCP-1, IP-10, Eotaxin 1, and 
GM-CSF) and IL-12, IFN-γ , and IL-4.
An exacerbation of pro-inflammatory cytokine and chemokine production, however, was observed in the pul-
monary micro-environment due to co-infection. Significantly increased production of IL-1β , IL-6, and IP-10 was 
observed in co-infected lung as compared to Mtb-infected lung. Significant increases in IL-8 and MIP-1α were 
observed in co-infected lung while these molecules were not increased following Mtb or HIV mono-infection. 
Activation of IL-10 occurred following Mtb infection and was further increased due to co-infection, although this 
effect of co-infection failed to reach significance (p = 0.07) due to variability among animals.
Pulmonary pneumonia and vascular occlusions develop as complications of HIV/Mtb 
co-infection. Interestingly, TB pneumonia and vascular occlusions were noted in several animals with 
co-infection, while similar pathologies were not seen in in mono-infections. As shown in Fig. 7, alveolar spaces in 
co-infected HuMouse lung contained inflammatory cells and exudate consistent with TB pneumonia identified 
in infected human tissues. The development of TB pneumonia in immunocompromised persons including those 
Figure 4. HIV co-infection exacerbates Mtb pathology in HuMouse lung. Determination of pulmonary 
pathology using H&E visualization and light microscopy. (A) Representative lung from HuMouse 5 wk p.i. 
with Mtb or Mtb/HIV demonstrating increased number and/or size of TB lesions due to HIV. (B) Area of the 
lung, shown as a %, occupied by the average individual granuloma, or total granulomatous tissue, in tissue of 
HuMice infected with Mtb (n = 6) or Mtb/HIV (n = 8) as determined using Image J software. (C) Diffuse lesion 
development and poor containment of Mtb-infected macrophages due to HIV co-infection. (D) Increased 
pulmonary pathology and bacterial burden in necrotic tissue in co-infected animals. Insets show detection 
of AFB using Ziehl-Neelson staining in matched tissue sections. Statistically significant differences among 
treatment groups are designated as follows: *p < 0.05.
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with HIV/AIDS has been described22. Observation of this feature is an important endpoint that supports the 
validity of the HuMouse model to study TB/HIV. Additionally, infiltration of small vessels by mononuclear cells 
with endothelialitis and luminal narrowing in co-infected HuMouse lung was also observed. To confirm this find-
ing, a pentachrome stain (Movat) was employed which identifies nuclei, elastin, cartilage, reticular fibers, mucin, 
fibrin, and muscle. Visualization of the black elastin fibers definitively identified vascular occlusions as shown 
within a representative tissue in Fig. 7A. Similar vascular occlusions were identified in lung from our co-infected 
human lung reference tissues as illustrated in Fig. 7B. Development of vascular occlusions is a pathology that has 
previously been noted in advanced stages of human TB34–38, but has not been associated with HIV to our knowl-
edge. Development of bronchiole obstructions in the lung of co-infected mice (Fig. 7C) was observed. Bronchiole 
obstructions can occur in advanced TB in human subjects39,40 and we have previously described development of 
this pathology in HuMice at later stages (> 7 wk) of Mtb infection20. At earlier stages of infection (5 wk) in the 
HuMouse, we observed in two independent studies that bronchiole obstructions developed only in the lungs of 
co-infected animals.
Figure 5. Co-infection with HIV promotes neutrophil accumulation in pulmonary TB granulomas. 
(A) Visualization of lung pathology due to Mtb infection and Mtb/HIV co-infection in reference human 
(top), and representative humanized mouse (bottom) lung, demonstrating diffuse lesions and tissue damage. 
(B), Determination of neutrophil accumulation due to Mtb or Mtb/HIV infection through detection of 
myeloperoxidase (MPO) in infected human (top) and HuMouse lung (bottom) tissue. Top inset shows non-
specific control staining for fast red in the necrotic lesion. Bottom inset shows representative tissue from 
HuMouse with HIV mono-infection, demonstrating lack a paucity of neutrophils and non-remarkable 
pathology in the absence of Mtb co-infection.
www.nature.com/scientificreports/
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Discussion
Evidence-based studies that can inform development of novel countermeasures to reduce and treat TB/HIV are 
critically needed. Our description of dual disease here is the first, to our knowledge, to demonstrate the appli-
cation of HuMice in understanding the pathogenesis of TB/HIV, or of any viral and bacterial co-infection. In 
the absence of Mtb, infection with HIV in HuMice led to systemic viral propagation and random distribution 
of HIV + cells to the lung interstitium. In contrast, a definitive localization of HIV + cells to the periphery of 
TB granulomas was observed in HuMouse and human lung as previously described in a rhesus macaque model 
of SIV/TB11. These are important observations as a small number of HIV-infected cells can exert local immune 
modulatory activity through the effects of cytokines (e.g IL-10) and potentially toxic HIV proteins (e.g. gp120, 
tat, nef)41,42. These observations provide evidence to support the theory that the inflammatory response to Mtb 
infection may recruit HIV + cells to the granuloma, which in turn disrupts local protective innate and acquired 
immune function required at this critical site for containment of Mtb in the host lung.
HIV infection in HuMice markedly altered the host immune containment of pulmonary Mtb infection similar 
to the accelerated progression of TB disease in people with HIV25. Infection with HIV may be disrupting innate 
immune processes involved in bacterial killing or antigen presention by macrophages as demonstrated using ex 
vivo analysis of human cells43–45 or by impairing T cell helper and/or cytotoxic activity that restricts Mtb growth 
in macrophages4,46–48. In our model of co-infection, we observed in vivo effects prior to significant loss of CD4+ 
T cells in peripheral blood; the latter is a clinical indicator of generalized immune suppression in human sub-
jects with HIV47,49. At this early stage of infection, we did not observe increased HIV replication when assessing 
peripheral and splenic viral loads as has been observed in the BAL fluid of some human subjects with active TB50. 
Consistent with the limited observations of co-infected human lung13,14 we found that disorganized Mtb lesions 
develop in the setting of HIV infection in the HuMouse. Our results, however, demonstrate that diffuse and 
poorly organized Mtb lesions can develop from the onset of acute co-infection. This is important, as the effect of 
HIV to compromise TB host defense is postulated to be due to HIV-mediated deterioration of the already devel-
oped protective granuloma structure, leading to bacterial escape and dissemination9. That scenario is most likely 
to apply to patients with latent TB, or a resolving TB infections, who later become infected with HIV. In those 
with an active HIV infection who subsequently are infected with Mtb, the initial results in the HuMouse model 
imply that de novo formation of the granuloma is compromised and perhaps occurs prior to lowering of CD4+ T 
cell counts in peripheral blood.
A surprising finding is that inappropriate or dysregulated immune responses, as opposed to immune sup-
pression, can occur at an early stage of co-infection. It is important to note that the current studies were not 
extended to include late stages of disease characterized by CD4 + T cell loss and AIDS. In support of an earlier 
morphological description of cellular influx in a co-infected lung14, our analysis revealed neutrophils as the defin-
itive inflammatory cell type accumulating in the lung of co-infected human subjects, and HuMice, at sites of Mtb 
proliferation. In the absence of HIV infection, neutrophils have a well-defined protective role during the early 
immune response to Mtb32,51 but are associated with pulmonary pathology when the infection fails to resolve52,53. 
The tissue destruction mediated by neutrophil degranulation and the accumulating debris from dying neutrophils 
provides an environment that is believed to be favorable for Mtb proliferation21. Our findings introduce a mecha-
nistic concept that could explain why increased blood neutrophil counts in HIV co-infected patients is associated 
with greater TB disease severity54. Our studies have also suggested candidate inflammatory mediators (e.g. IL-1β , 
CXCL5, IL-8) that could promote excessive neutrophil recruitment in co-infected lung. Interestingly, these effects 
Figure 6. HIV co-infection activates excessive pro-inflammatory cytokine and chemokine responses to Mtb 
in the lung. Lung supernatants from HuMice harvested 5 wk p.i. with Mtb or Mtb/HIV were used to determine 
activation of human cytokines and chemokines by multiplex ELISA. (A) Expression of human cytokines, and 
(B) chemokines, in non-, HIV-, Mtb-, and Mtb/HIV-infected HuMice. Data are means ± SEM from samples of 
non-infected control (n = 4) and three infection groups of Humice including HIV (n = 3), Mtb (n = 6) and Mtb/
HIV (n = 8). Statistically significant differences compared to non-infected controls are designated as follows: 
*p < 0.05; **p < 0.01; ***p < 0.001. Significant differences among infected groups are shown as ̵Ip < 0.05;  
̵I  ̵Ip < 0.01; ̵I  ̵I  ̵Ip < 0.001.
www.nature.com/scientificreports/
8Scientific RepoRts | 6:21522 | DOI: 10.1038/srep21522
are observed in the absence of HIV-associated defects in several cytokines (IFN-γ , IL-12, and TFN-α ) that play 
important roles in TB immunity55,56.
The development of vascular occlusions, bronchial obstructions, and bacterial pneumonia that we observed 
in co-infected animals and human reference tissue is consistent with the effects of exacerbated inflammation. 
Bacterial pneumonia is known to occur in people who are immune compromised who become infected with 
Mtb22, while vascular occlusions and bronchial obstructions are features observed in advanced TB disease35,37,38. 
We have previously reported development of bronchial obstructions and pneumonia in HuMice at later stages 
of Mtb infection (> 7 wk p.i.) or following infection with a larger i.n. Mtb dose20. Our results in the HuMouse, 
then, suggest that HIV co-infection may accelerate the TB disease process by promoting specific aspects of the 
inflammatory process.
In summary, these studies describe a novel model that has been successfully applied to increase our under-
standing of TB/HIV co-infection pathobiology. These initial findings may provide a basis for the conflicting 
evidence for both immune activation and immune suppression in co-infected human subjects. Speculatively, 
co-infection may drive non-protective inflammation during early stages of HIV disease while immune com-
promise, including loss of IFN-γ , predominates once CD4+ T cell depletion ensues. In future studies it will be 
important to determine if these features of inflammatory pathology are promoted by the increased bacterial load 
in the HIV-compromised host, or if HIV-driven inflammation may play a more direct role in supporting the 
Mtb growth that subsequently accelerates TB disease progression. This is quite intriguing given recent studies 
that demonstrate inflammatory processes may augment M.tb proliferation57,58 independent of the effect of tissue 
destruction to provide a favorable environment for Mtb growth. Long term, the HuMouse may serve as an impor-
tant pre-clinical model to identify mechanisms of co-infection pathobiology and test therapeutic interventions 
prior to use in NHPs or human subjects.
Materials and Methods
Ethics statement. All animal procedures were performed in accordance with the regulations of the NIH 
Office of Laboratory Animal Welfare and were approved by the University of Texas Medical Branch (UTMB) 
Institutional Animal Care and Use Committee (IACUC). Human fetal tissue used in generation of humanized 
mice was obtained via a non-profit partner (Advanced Bioscience Resources, Alameda, CA) as approved under 
exemption 4 in the HHS regulations (45 CFR Part 46) as previously described20.
Animal Experiments. Humanized BLT mice were generated as we have previously described20. HIV 
(JR-CSF strain) was obtained from the Baylor College of Medicine Center for AIDS Research Virology Core 
and stored at − 80 °C until use. The JR-CSF strain is a human clinical HIV-1 isolate that is classically defined 
Figure 7. Pulmonary pneumonia and vascular occlusions develop as complications of HIV/Mtb co-
infection. Visualization of lung pathology due to Mtb infection and Mtb/HIV co-infection in representative 
HuMice (top) and reference human (bottom) lung. (A) Movat staining reveals vascular occlusion as indicated 
by blockage interior to elastin bands of vessel (black). Visualization of H&E staining demonstrates (B) TB 
pneumonia and (C) bronchial occlusions in co-infected HuMouse (top) and human (bottom) lung.
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as M-tropic and infects both monocyte/macrophage and CD4+ T cells. HIV was diluted in PBS and mice were 
infected with a 2,500 TCID50 via tail vein infection as described17. Infection with the H37Rv (tdTomato) strain 
of Mtb59 was performed using 250 CFU diluted in 40 ul of Dulbecco’s Phosphate-Buffered Saline (PBS, Cellgro, 
Manassas, VA, USA) via an intranasal route (20 ul/nare) as described20. Animal experiments were repeated in 
an independent group generated from an additional human tissue donor. Humanized mice are challenging to 
generate and animal numbers were a limitation. Two independent studies with non-infected animals (n = 2/
study), Mtb-infected (n = 3/study) and Mtb/HIV-infected (n = 4/study) were performed. Three HIV-infected 
control animals were included only in one study. All animal experiments and work with Mtb were performed in a 
CDC-approved animal biological safety level-3 (ABSL-3) and BSL3 facilities in the Galveston National Laboratory 
in accordance with biosafety procedures approved by the UTMB Environmental Health and Safety Division.
Bacterial and Viral Load. Following aseptic removal at 5 wk post Mtb infection, organs (lung and liver) 
were placed into 1 ml of PBS in 15 ml small tissue grinders (Kendall, Mansfield, MA, USA) for tissue homogeniza-
tion. Serial dilutions of homogenized organ samples were prepared in PBS to perform limiting dilution CFU enu-
meration as described60. All studies were performed in a CDC-approved biological safety level-3 (BSL-3) facility. 
For viral quantification, plasma and supernatants from disrupted spleen were stored frozen at − 80 °C. Plasma and 
splenic supernatants were then used to detect HIV p24 capsid protein using a clinical ELISA test (Zeptometrix, 
Buffalo, NY). Levels of p24 were quantified by generating a standard curve using the standards provided in the kit. 
Values were generated by linear regression to the standard curve as recommended by the manufacturer.
Human Reference Tissue. Human lung tissue was obtained in collaboration with the UTMB Autopsy ser-
vices from archival formalin-fixed paraffin embedded tissue obtained between 1996 and 2001. The reference 
samples included in Figs 1,4, and 7 are from decedents with confirmed TB or TB/HIV disease based on chart his-
tory and post-mortem analysis. Tissue were fixed in 10% formalin and embedded in paraffin until use to generate 
sections for analysis by histopathology and immunohistochemistry.
Flow Cytometry. Levels of CD4+ T-cells were assessed pre- and post-infection by multi-variate flow cyto-
metric assessment of peripheral blood. Blood was collected from the tail vein of HuMice into 300 μ l of 3 mM 
ethylenediaminetetraacetic acid (EDTA, Capitol Scientific, Austin, TX, USA). Red Blood Cell Lysis Buffer (Sigma, 
St. Louis, MO, USA) was used according to the manufacturer to isolate the peripheral blood mononuclear cells 
(PBMCs). To reduce non-specific binding, PBMCs were incubated with CD16/CD32 Fc Block (BD Biosciences, 
San Jose, CA, USA). The following antibodies specific to human lymphocyte surface markers were used to stain 
the cells: AmCyan-CD45, APC-Cy7-CD3, and Pacific Blue-CD4. A total of 50,000 gated events were collected 
in a live cell gate using a BD LSR II (Fortessa) flow cytometer (BD Biosciences) in the UTMB Flow Cytometry 
and Cell Sorting Core Facility. Analysis of data was performed by FCS Express (De Novo, Los Angeles, CA, USA) 
software. Isotype matched antibodies were used to control for background fluorescence. Cells were selected based 
on expression of the human CD45 marker and further analyzed for human CD3 and CD4 phenotype.
Immunohistochemistry. Lung tissue sections from formalin-fixed, paraffin embedded HuMouse or human 
lung were deparaffinized and washed in 0.05% PBST. Following deparaffinization, antigen retrieval was per-
formed by 25 min incubation in citrate buffer, pH 6 (Dako) at 95–100 °C in a rice steamer. Samples were then 
washed with 0.05% PBST and incubated with monoclonal antibodies to MPO (at a dilution of 1:50; Abcam; ref 
ab45977-100) for two hours at room temperature or HIVp24 (at a dilution of 1:50; Dako; clone Kal-1) overnight 
at 4 °C. Sections were stained with Permanent Red using the Dako EnVision System with Mayer’s Hematoxylin 
as the counter stain. Images were taken using an Olympus BX53 microscope equipped with an Olympus DP71 
camera.
Pathology. At specified time points, following aseptic removal of organs, the remaining half of tissues were 
placed in 10% Neutral Buffered Formalin (Statlab, McKinney, TX, USA) for 48 hours to inactivate infectious 
agent, changed after 24 hours, and finally stored in 70% ethanol. Tissues were embedded in paraffin then stained 
with hematoxylin and eosin (H&E) and additional sections were stained using the Ziehl-Neelson method to vis-
ualize acid-fact bacteria (AFB) to detect M.tb bacilli. A 5 color chromagen (Movats) stain was performed to visu-
alize vascular pathology including elastin, collagen, fibrin, mucin, and muscle fibers. Processing and staining for 
H&E, AFB, and Movats was performed by the University of Texas Medical Branch, Research Histopathology Core 
Facility. Lung tissue was evaluated by a trained pathologist with expertise in tuberculosis disease progression, 
with confirmation done in a slide blinded manner. Granuloma number was quantified from the entire section of 
mouse lung. The average size of each granuloma and the total amount of granulomatous tissue in the whole lung 
was quantified using digital software (NIH Image J; developed at the U.S. National Institutes of Health and avail-
able on the Internet at http://rsb.info.nih.gov/nih-image/). The percent of granulomatous tissue was calculated as 
a percent of total lung area as described61.
Cytokine/Chemokine Quantification. Supernatants from disrupted lung were harvested during necropsy 
5 wk post-M.tb infection and stored frozen at − 80 °C. Samples were subsequently γ -irradiated on dry ice using a 
JL Shepherd Model 109–68 Cobalt-60 Research Irradiator (JL Shepherd & Associates, San Fernando, CA 91340) 
until 5 MRAD of exposure was reached. A non-diluted test sample was plated on 7H11 agar and incubated at 
37 °C for > 5 weeks to ensure sterility prior to removing samples from biocontainment. Lung supernatants were 
used in performance of a multiplex ELISA (Bio-rad Bio-plex Pro™ human cytokine 27-plex kit) according to 
the manufacturer’s instructions to assess changes in expression of human cytokines: IL-1β , IL-1ra, IL-2, IL-4, 
IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, IP-10, FGF basic, Eotaxin, G-CSF, GM-CSF, 
IFN-γ , MCP-1 (MCAF), MIP-1α , MIP-1β , PDGF-BB, RANTES, TNF-α , VEGF. Values for cytokines where cross 
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reactivity between human detection reagents and mouse cytokines could confound data (e.g. VEGF, IL-13) were 
excluded from the analysis. Levels of each cytokine were quantified by generating a standard curve using the 
standards provided in the kit. Values were generated by linear regression to the standard curve as recommended 
by the manufacturer and as described62. Values that were below the extrapolated range (< OOR) were set to 0.
Statistics. Data are shown as mean ± SEM. One-way ANOVA followed by a Dunnetts multiple comparison 
test was used for multiple group comparisons (GraphPad Software v5.0). Statistically significant values are desig-
nated as follows: *p < 0.05; **p < 0.01; ***p < 0.001. The strength of association between viral load and bacterial 
burden or lung pathology was computed using the Spearman correlation coefficient (GraphPad Software v5.0).
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